Lunit
Korean AI company spanning mammography reading (INSIGHT MMG), breast-density risk (Volpara), and AI pathology for immunotherapy biomarkers.
21 studies at ECR 2026 covering INSIGHT MMG, Scorecard (ex-Volpara density), and INSIGHT CXR; a large Dutch randomised trial using Scorecard showed supplemental MRI in dense breasts reduced advanced cancer incidence. Lunit SCOPE pathology AI partnered with Labcorp and CellCarta (2025-26) for companion diagnostics.
Pages like this
not linked directly; found by shared links- Key paperMASAI: AI-supported mammography screening finds more cancers with half the radiologist workload
Shares Roll out AI-supported mammography nationally as a stepped-wedge trial, Set each woman's mammogram interval from her last mammogram, using AI risk, Mammography & tomosynthesis, AI in radiology.
- CompanyAidoc
Shares No clinical claims for imaging-derived biomarkers without phantom and standards compliance, AI clears the normal lung screening scans so radiologists read only the suspicious ones, AI-assisted central imaging reads to cut endpoint cost and variability, AI in radiology.
- IdeaPathologist assistants plus AI triage to multiply pathologist capacity
Shares AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions, Digital pathology & AI, Not enough oncologists, nurses, pathologists, physicists, AI that is built but not validated or deployed.
- IdeaA dedicated fund for randomised trials of cancer AI with patient outcomes
Shares Mammography & tomosynthesis, AI in radiology, Digital pathology & AI, AI that is built but not validated or deployed.
- TechnologyMirai (MIT breast cancer risk from mammograms)
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- CompanyPaige AI
Shares AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions, Turn the map of immune cells inside a tumour into a standardised test, Digital pathology & AI, Not enough oncologists, nurses, pathologists, physicists.
- IdeaAI quantification of HER2-low and HER2-ultralow
Shares AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions, Digital pathology & AI, AI that is built but not validated or deployed, Triple-negative breast cancer (TNBC).
- PersonLaura J. Esserman
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.